Morning Read: Would you rather be Valeant or Walgreens right now?
Also, doctors still dislike direct-to-consumer genetics; Mayo will pay $1 billion for its EMR face-lift, and can we all admit we measure patient satisfaction incorrectly?
#HIMSS16 Day 1 buzz: Omaha! Omaha! Here are the early HIMSS predictions
Even before the Day 1 keynote, storm clouds gather for McKesson and new products - including a protable telehealth kit - are announced.
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Morning Read: Valeant’s Michael Pearson is back at work, where is all the HIMSS16 coverage?
Also, CEO succession plans at GSK, Sanofi's plans to buy orphan drug companies, doctors healthcare social media habits and long looks at Bernie Sanders and Donald Trump's health plans.
Morning Read: Valeant loses $6 billion in value, the digital health drumbeat hits Harvard
Plus, a new Parkinson's project in Britain, a $70M fund-raise for Alzheimer's drugs, Tenet outlines its financials, and more HIMSS 2016 advice.
Morning Read: A new global bioscience fund launches, HIMSS hype starts today
Also, fresh backing for a Lilly Asia Ventures company; how you can tie Apple's privacy fight back to healthcare; and the push to redefine network adequacy for health insurance companies.
$1.5 billion reasons why healthcare investors may be able to find the Midwest on a map
Most states are now regularly attracting 10 figures in total investing.
Morning Read: Pfizer co-launches healthcare accelerator around sleep, stress, aging and beyond
Also, new views on the "war on sciences," depressing stats about caregivers and more evidence on the right way to encourage wellness.
Cloud Pharmaceuticals eyeing $10 million round
It also projects $5 million in revenue this year.
Morning Read: Does the medical industry do poorly with disasters by design?
Also, the real problem with technology in healthcare and high hopes for Opdivo
Morning Read: Iowa caucus results show single payer lives (at least in Bernie Sanders’ mind)
Also, Index Ventures spins off a new biotech fund with the help of Johnson & Johnson and GlaxoSmithKline, Sanofi will take a shot at a Zika vaccine and IBM Watson teams with the American Heart Association.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Morning Read: Will the Iowa caucuses teach us about the future of healthcare? (Let’s hope not)
Also, Britain OKs gene editing in the human embryo, Illumina makes new biobank deals and we'll get a peek at Google's healthcare numbers today.
Morning Read: A nice win for direct-to-consumer healthcare, and about those Obamacare stats…
Also, big precision medicine news from Oracle, GSK takes on the Zika virus, and JJDC invests in another genomics company.
Morning Read: Does a Medicare suspension loom for Theranos?
Also, Big Pharma starts a $57 million fund with British universities and a new approach to workplace wellness by employers.
Who will play Martin Shkreli in a ‘100 percent’ happening Martin Shkreli movie?
Oh, and he may just burn that Wu Tang clan album.
This week on MedHeads: The future of health IT after Meaningful Use
Dr. Linda Girgis and Dr. Peter Basch join MedCity News' Neil Versel